Evidence map›Paper›PMID 35008325›Full record

ArticleCancers2021

Correlation of Somatostatin Receptor 1-5 Expression, [

Susanna Majala, Tiina Vesterinen, Hanna Seppänen, Harri Mustonen, Jari Sundström, Camilla Schalin-Jäntti, Risto Gullichsen, Jukka Schildt, Jukka Kemppainen, Johanna Arola and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Susanna MajalaDepartment of Surgery, Division of Digestive Surgery and Urology, Turku University Hospital, University of Turku, P.O. Box 52, FIN-20521 Turku, Finland.
Tiina VesterinenHUSLAB, HUS Diagnostic Center, Department of Pathology, Helsinki University Hospital, University of Helsinki, P.O. Box 400, FIN-00029 Helsinki, Finland.ORCID 0000-0003-2997-0337
Hanna SeppänenTranslational Cancer Medicine Research Program, Department of Surgery, Faculty of Medicine, Helsinki University Hospital, University of Helsinki, P.O. Box 340, FIN-00029 Helsinki, Finland.
Harri MustonenTranslational Cancer Medicine Research Program, Department of Surgery, Faculty of Medicine, Helsinki University Hospital, University of Helsinki, P.O. Box 340, FIN-00029 Helsinki, Finland.
Jari SundströmDepartment of Pathology, Turku University Hospital, P.O. Box 52, FIN-20521 Turku, Finland.
Camilla Schalin-JänttiAbdominal Center, Division of Endocrinology, Helsinki University Hospital, University of Helsinki, P.O. Box 340, FIN-00029 Helsinki, Finland.
Risto GullichsenDepartment of Surgery, Division of Digestive Surgery and Urology, Turku University Hospital, University of Turku, P.O. Box 52, FIN-20521 Turku, Finland.
Jukka SchildtDepartment of Clinical Physiology and Nuclear Medicine, Helsinki University Hospital, Haartmaninkatu 4, P.O. Box 340, FIN-00029 Helsinki, Finland.
Jukka KemppainenTurku PET Centre, Turku University Hospital, P.O. Box 52, FIN-20521 Turku, Finland.
Johanna ArolaHUSLAB, HUS Diagnostic Center, Department of Pathology, Helsinki University Hospital, University of Helsinki, P.O. Box 400, FIN-00029 Helsinki, Finland.
Saila KauhanenDepartment of Surgery, Division of Digestive Surgery and Urology, Turku University Hospital, University of Turku, P.O. Box 52, FIN-20521 Turku, Finland.ORCID 0000-0002-7062-7162
University of Helsinki · FIUniversity of Turku · FITurku University Hospital · FIHelsinki University Hospital · FI

Funding

Cancer Foundation Finland WBS 4707973Helsinki University Hospital Research Fund TYH2021204Hus Diagnostic Centre Research Fund Y780021084Liv&Hälsa Foundation WBS 4708047Mary and Georg C. Ehrnrooth Foundation 202110027The Finnish Medical Foundation 2547Turku University Hospital Research Services 13920
6 · The paper itself

Abstract

purposeThe aim of this study was to correlate immunohistochemical (IHC) tissue levels of SSTR1-5 with the receptor density generated from [

methodsTwenty-one patients with a total of thirty-five NF-PNEN-lesions and twenty-one histologically confirmed lymph node metastases (LN+) were included in this prospective study. Twenty patients were operated on, and one underwent endoscopic ultrasonography and core-needle biopsy. PET/CT with both [

resultsExpression of SSTR1-5 was detected in 74%, 91%, 80%, 14%, and 77% of NF-PNENs. There was a concordance of SSTR2 IHC with positive/negative [

conclusionSSTR2 was the only SSTR subtype to correlate with [

Indexed as

immunohistochemistrynon-functional pancreatic neuroendocrine neoplasmpositron emission tomographyprospective studysomatostatin receptorssurgical management

Identifiers

PMID35008325
PMCPMC8750461
OpenAlexW4200338069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.